CDK4/6 inhibitors

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

CDK4/6 inhibitors
Jun 20, 2025, 02:19 | Drugs
Is Tamoxifen Chemotherapy? Understanding Its Role in Breast Cancer Treatment
Cancer treatment encompasses a range of therapeutic approaches, each with distinct mechanisms and clinical applications.…
Jun 14, 2025, 17:40 | Blog
Paolo Tarantino: What Patients Are Eligible for Adjuvant CDK4/6 Inhibitors?
Paolo Tarantino, 2025 Yvonne’s Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared…
Jun 9, 2025, 18:05 | Science
Armando Orlandi Evaluates CDK4/6 Inhibitors in Adjuvant Breast Cancer Using NNT Metric
Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post…
Jun 3, 2025, 11:34 | Blog
Armando Orlandi: Time to Challenge the Paradigm - CDK4/6 Inhibitors in Visceral Crisis 
Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, posted on LinkedIn:…
Jun 1, 2025, 15:32 | Insight
Olubukola Ayodele on INAVO120 Inavolisib Combo Results at ASCO 2025
Olubukola Ayodele, Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, posted on…
Apr 18, 2025, 00:15 | Oncolibrary
New Paper Alert: Adjuvant CDK4/6 Inhibitors: Promising or Problematic? A Critical Review of the Evidence.
CDK4/6 inhibitors, widely celebrated for their role in managing metastatic ER-positive breast cancer, have garnered…
Feb 17, 2025, 05:45 | Drugs
Comparative OS of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− mBC in the US real-world setting
Dana-Fraber's Breast Oncology Center shared an article on X recently published on ESMO Open authored…
Dec 22, 2024, 08:13 | Science
Liang Cheng: Advancements in biomarkers and molecular diagnostics in HR+ Breast Cancer
Liang Cheng, Vice Chair for Translational Research at The Warren Alpert Medical School of Brown…
Dec 12, 2024, 13:36 | Blog
Olubukola Ayodele: Summary of the EMBER-3 trial
Olubukola Ayodele, Consultant Medical Oncologist at the University Hospitals of Leicester NHS Trust, posted on…
Dec 2, 2024, 15:28 | Insight
Gabe Sonke: Grateful to all patients who participated in the SONIA trial
Gabe Sonke, Professor of Clinical Oncology at the Netherlands Cancer Institute, shared a post by…
Aug 8, 2024, 20:04 | Insight
Yakup Ergün: Is completion axillary lymph node dissection necessary for adjuvant CDK4/6 inhibitors?
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X: “SENOMAC post-hoc analysis: Is…
Aug 5, 2024, 14:29 | Insight
Anas Hamad: The first study in the MENA region to compare the 3 CDK4/6 Inhibitors in one analysis
Anas Hamad, Director of Pharmacy Department at National Center for Cancer Care and Research, shared…
Jul 31, 2024, 10:36 | Blog
Great lecture on endocrine therapy for breast cancer by Matteo Lambertini
Matteo Lambertini shared a post by Tatsunori Shimoi, Medical Doctor at National Cancer Center Hospital, on…
Jun 14, 2024, 09:30 | Blog
Upcoming webinar on "Overcoming Resistance" led by Michael Wick - The START Center for Cancer Research
The START Center for Cancer Research shared on LinkedIn:       . "Don't miss our…
May 31, 2024, 10:41 | Blog
Jason A. Mouabbi: Here are my anticipated Top 3 breast cancer presentations for ASCO24
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared a post on X:…
May 26, 2024, 06:49 | Societies
Paolo Tarantino: Less than a week to what promises to be a terrific ASCO24
Paolo Tarantino recently shared a post on X: "Less than a week to what promises…
May 24, 2024, 14:53 | Insight
Timothée Olivier: Our analysis tion about adjuvant use of CDK4/6 inhibitors in early breast cancer
Vinay Prasad, Professor of Epidemiology and Biostatistics at the University of California, San Francisco, shared a…
May 15, 2024, 09:03 | Blog
Stephanie Graff: Honored to join Wolfgang Janni and Carlos Barrios at ESMO Breast 24
Stephanie Graff shared a post on X: “Leaving soon for ESMO Breast 24. Honored to…
Apr 3, 2024, 13:35 | Insight
Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes
Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on…
Apr 2, 2024, 18:47 | Drugs
A Reflection on a Decade-Long Clinical Trial by Wafik S. El-Deiry
Wafik S. El-Deiry, Director at the Legorreta Cancer Center at Brown University, shared a post…
Mar 21, 2024, 10:46 | Insight
Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence - UCLA Health
Drug regimen significantly improves invasive disease-free survival for patients with stage 2 or 3 HR-positive,…
Dec 14, 2023, 16:23 | Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Nov 8, 2023, 18:09 | Societies
ASCO has been awarded an $11 million grant from PCORI to support a clinical trial co-led by Erica Mayer - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared on LinkedIn: "The American Society of Clinical Oncology (ASCO) has been awarded an $11…
Oct 28, 2023, 11:36 | Blog
Stephanie Graff: The relationship of PIM1 and metastatic breast cancer, potential therapeutic implications with CDK4/6 inhibitors and more!
Quoting Stephanie Graff on LinkedIn: ''That’s a wrap on the 2023 European Society of Medical…
Sep 21, 2023, 17:56 | Blog
Karima Oualla: We invite you to fill out this survey that takes no more than 3 minutes to complete.
Quoting Karima Oualla, Professor of Medical Oncology at Hassan II University Hospital, on LinkedIn: "Dear…
All: 25 Posts: 1 - 100
Special Coverage